Hikma reveals OTC ambition
This article was originally published in OTC Bulletin & The Rose Sheet
Hikma’s recent tie-up with Perrigo in the Middle East and North Africa (MENA) represents a “long-term, very important” strategic play by the Jordanian firm to develop a presence in the global consumer healthcare market, insisted chief executive officer Siggi Olafsson.
You may also be interested in...
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.